The CD70-CD27 axis in oncology: the new kids on the block
The immune checkpoint molecule CD70 and its receptor CD27 are aberrantly expressed in many hematological and solid malignancies. Dysregulation of the CD70-CD27 axis within the tumor and its microenvironment is associated with tumor progression and immunosuppression. This is in contrast to physiologi...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734249/ https://www.ncbi.nlm.nih.gov/pubmed/34991665 http://dx.doi.org/10.1186/s13046-021-02215-y |
_version_ | 1784627977154199552 |
---|---|
author | Flieswasser, Tal Van den Eynde, Astrid Van Audenaerde, Jonas De Waele, Jorrit Lardon, Filip Riether, Carsten de Haard, Hans Smits, Evelien Pauwels, Patrick Jacobs, Julie |
author_facet | Flieswasser, Tal Van den Eynde, Astrid Van Audenaerde, Jonas De Waele, Jorrit Lardon, Filip Riether, Carsten de Haard, Hans Smits, Evelien Pauwels, Patrick Jacobs, Julie |
author_sort | Flieswasser, Tal |
collection | PubMed |
description | The immune checkpoint molecule CD70 and its receptor CD27 are aberrantly expressed in many hematological and solid malignancies. Dysregulation of the CD70-CD27 axis within the tumor and its microenvironment is associated with tumor progression and immunosuppression. This is in contrast to physiological conditions, where tightly controlled expression of CD70 and CD27 plays a role in co-stimulation in immune responses. In hematological malignancies, cancer cells co-express CD70 and CD27 promoting stemness, proliferation and survival of malignancy. In solid tumors, only expression of CD70 is present on the tumor cells which can facilitate immune evasion through CD27 expression in the tumor microenvironment. The discovery of these tumor promoting and immunosuppressive effects of the CD70-CD27 axis has unfolded a novel target in the field of oncology, CD70. In this review, we thoroughly discuss current insights into expression patterns and the role of the CD70-CD27 axis in hematological and solid malignancies, its effect on the tumor microenvironment and (pre)clinical therapeutic strategies. |
format | Online Article Text |
id | pubmed-8734249 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-87342492022-01-07 The CD70-CD27 axis in oncology: the new kids on the block Flieswasser, Tal Van den Eynde, Astrid Van Audenaerde, Jonas De Waele, Jorrit Lardon, Filip Riether, Carsten de Haard, Hans Smits, Evelien Pauwels, Patrick Jacobs, Julie J Exp Clin Cancer Res Review The immune checkpoint molecule CD70 and its receptor CD27 are aberrantly expressed in many hematological and solid malignancies. Dysregulation of the CD70-CD27 axis within the tumor and its microenvironment is associated with tumor progression and immunosuppression. This is in contrast to physiological conditions, where tightly controlled expression of CD70 and CD27 plays a role in co-stimulation in immune responses. In hematological malignancies, cancer cells co-express CD70 and CD27 promoting stemness, proliferation and survival of malignancy. In solid tumors, only expression of CD70 is present on the tumor cells which can facilitate immune evasion through CD27 expression in the tumor microenvironment. The discovery of these tumor promoting and immunosuppressive effects of the CD70-CD27 axis has unfolded a novel target in the field of oncology, CD70. In this review, we thoroughly discuss current insights into expression patterns and the role of the CD70-CD27 axis in hematological and solid malignancies, its effect on the tumor microenvironment and (pre)clinical therapeutic strategies. BioMed Central 2022-01-06 /pmc/articles/PMC8734249/ /pubmed/34991665 http://dx.doi.org/10.1186/s13046-021-02215-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Flieswasser, Tal Van den Eynde, Astrid Van Audenaerde, Jonas De Waele, Jorrit Lardon, Filip Riether, Carsten de Haard, Hans Smits, Evelien Pauwels, Patrick Jacobs, Julie The CD70-CD27 axis in oncology: the new kids on the block |
title | The CD70-CD27 axis in oncology: the new kids on the block |
title_full | The CD70-CD27 axis in oncology: the new kids on the block |
title_fullStr | The CD70-CD27 axis in oncology: the new kids on the block |
title_full_unstemmed | The CD70-CD27 axis in oncology: the new kids on the block |
title_short | The CD70-CD27 axis in oncology: the new kids on the block |
title_sort | cd70-cd27 axis in oncology: the new kids on the block |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734249/ https://www.ncbi.nlm.nih.gov/pubmed/34991665 http://dx.doi.org/10.1186/s13046-021-02215-y |
work_keys_str_mv | AT flieswassertal thecd70cd27axisinoncologythenewkidsontheblock AT vandeneyndeastrid thecd70cd27axisinoncologythenewkidsontheblock AT vanaudenaerdejonas thecd70cd27axisinoncologythenewkidsontheblock AT dewaelejorrit thecd70cd27axisinoncologythenewkidsontheblock AT lardonfilip thecd70cd27axisinoncologythenewkidsontheblock AT riethercarsten thecd70cd27axisinoncologythenewkidsontheblock AT dehaardhans thecd70cd27axisinoncologythenewkidsontheblock AT smitsevelien thecd70cd27axisinoncologythenewkidsontheblock AT pauwelspatrick thecd70cd27axisinoncologythenewkidsontheblock AT jacobsjulie thecd70cd27axisinoncologythenewkidsontheblock AT flieswassertal cd70cd27axisinoncologythenewkidsontheblock AT vandeneyndeastrid cd70cd27axisinoncologythenewkidsontheblock AT vanaudenaerdejonas cd70cd27axisinoncologythenewkidsontheblock AT dewaelejorrit cd70cd27axisinoncologythenewkidsontheblock AT lardonfilip cd70cd27axisinoncologythenewkidsontheblock AT riethercarsten cd70cd27axisinoncologythenewkidsontheblock AT dehaardhans cd70cd27axisinoncologythenewkidsontheblock AT smitsevelien cd70cd27axisinoncologythenewkidsontheblock AT pauwelspatrick cd70cd27axisinoncologythenewkidsontheblock AT jacobsjulie cd70cd27axisinoncologythenewkidsontheblock |